Navigation Links
Manure management reduces levels of antibiotics and antibiotic resistance genes
Date:11/28/2007

MADISON, WI, November 26, 2007- Antibiotic resistance is a growing human health concern. Researchers around the globe have found antibiotics and other pharmaceuticals to be present in surface waters and sediments, municipal wastewater, animal manure lagoons, and underlying groundwater. In a recent article in the November-December issue of Journal of Environmental Quality, researchers at Colorado State University (CSU) describe a study to find out if animal waste contributes to the spread of antibiotics and antibiotic resistance genes (ARG), and if they can be reduced by appropriate manure management practices.

In the study, funded by the USDA Agricultural Experiment Station at CSU and the National Science Foundation (NSF), researchers investigated the effects of manure management on the levels of antibiotics and ARG in manures. The study was conducted at two scales. In the pilot-scale experiment, horse manure was spiked with the antibiotics chlortetracycline, tylosin, and monensin and compared to horse manure that was not spiked with antibiotics to determine the response of ARG in unacclimated manures. In the large-scale experiment, dairy manure and beef feedlot manure, which were already acclimated to antibiotics, were monitored over time.

The manures were subjected to high-intensity management (HIM-amending with leaves and alfalfa, watering, and turning) and low-intensity management (LIM-no amending, watering, and turning) for six months. During this time, the levels of antibiotics were monitored using high-performance liquid chromatography (HPLC) and tandem mass spectrometry (MS/MS). In addition, two types of ARG that confer resistance to tetracycline, tet(W) and tet(O), were monitored using quantitative polymerase chain reaction (Q-PCR).

In the pilot study, chlortetracycline, tylosin, and monensin all dissipated more rapidly in the HIM-manure than in the LIM-manure. In the large-scale study, feedlot manure initially had higher concentrations of the several tetracycline antibiotics than the dairy manure. After four months of treatment, tet(W) and tet(O) decreased significantly in dairy manure, but two more months of treatment were necessary for similar reductions of ARG in the feedlot manures.

The results showed that HIM was more effective than LIM at increasing the rate of antibiotic dissipation, but it was not a significant factor in reducing the levels of ARG. The length of treatment time was the main factor in reducing the levels of both antibiotics and ARG. For manures with initially high levels of antibiotics, treatment times of at least six months may be necessary for a significant reduction in levels of antibiotics and ARG. The results also provided evidence that ARG may be present for extended time periods even after antibiotics have fully dissipated.

Scientists at Colorado State University are continuing research in this area by examining full-scale local on-farm waste management practices. Together this research will lead to a better understanding of possible ARG mitigation strategies so that best management practices can be developed to reduce the effects that animal waste may have on the spread of ARG.


'/>"/>

Contact: Sara Uttech
suttech@agronomy.org
608-268-4948
American Society of Agronomy
Source:Eurekalert

Related biology news :

1. Central targets may hinder wider waste management objectives
2. Upgraded IMG 2.3 Data Management System released by DOE JGI to eager user community
3. Fujitsu and HT Systems Partner to Provide Biometric Patient Identity Management
4. Fujitsu and HT Systems Partner to Provide Biometric Patient Identity Management
5. Parus Interactive Awarded Patent for Speech-Activated Remote System Management
6. Mosaic Intelligent Video Management System: Video Surveillance Just Got Smarter
7. Secure Services Corp. Achieves Milestone in United States Identity Protection with the Launch of the SSC SHAPE Card Management Solution
8. Fireproofing homes dramatically reduces forest fire size, according to new study
9. Clinical studies show REMICADE reduces incidence of bowel surgeries in ulcerative colitis patients
10. Exercise improves thinking, reduces diabetes risk in overweight children
11. Low levels of key protein may indicate pancreatic cancer risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/12/2017)...  Trovagene, Inc. (NASDAQ: TROV ), a ... that it has signed agreements with seven strategic partners ... Middle East for commercialization of the ... wave of international distribution agreements for Trovagene,s CLIA based ... The initial partners will introduce Trovagene,s liquid biopsy ...
(Date:1/11/2017)... -- Michael Johnson, co-founder of Visikol Inc. a company originally funded with ... to the elite "Forbes 30 Under 30" list in the Science ... 20 fields nationwide to be recognized as a leader in business ... ... a PhD candidate at Rutgers University. Visikol ...
(Date:1/4/2017)... thousands of attendees at this year,s International Consumer Electronics Show (CES), ... devices and services, will be featuring its new line of ULTRA CONNECT ... special CES Exhibit Suite , the new upper arm and wrist smart ... product platform.  Continue Reading ... ...
Breaking Biology News(10 mins):
(Date:1/11/2017)... ... January 11, 2017 , ... ... Research show early promise of the investigational anti-cancer agent tucatinib (formerly ONT-380) against ... previous treatment regimens. Twenty-seven percent of these heavily pretreated patients saw clinical benefit ...
(Date:1/11/2017)... , ... January 11, 2017 , ... ... year and costing healthcare systems more than $23.7 billion, healthcare systems are ... , Among the most common sepsis-causing pathogens are bacteria and the yeast ...
(Date:1/11/2017)... ... 11, 2017 , ... Symbios Technologies, Inc., a ... Science Foundation (NSF) has awarded Symbios a Small Business Innovation Research (SBIR) ... the Symbios Tubular Plasma Reactor™ (TPR™) by scaling the system for first customer ...
(Date:1/11/2017)... 11, 2017  GenVec, Inc. (NASDAQ: ... today that its chief scientific officer, Douglas ...  "AdenoVerse™ platform for translational development of innovative gene ... the upcoming Phacilitate Cell & Gene Therapy World ... Florida.  Dr. Brough,s presentation will highlight the utility ...
Breaking Biology Technology: